NMRA NMRA
Company Profile ↓Company Overview
NMRA (NMRA) is a publicly traded company listed on with a market capitalization of $280.56M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -2.42% |
| 6 Months: | -21.08% |
| 3 Months: | -30.00% |
| 1 Month: | -6.94% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 55.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 70.94M | 54.04M | 57.70M | 58.48M | 52.86M |
| Operating Income | - | - | -30.60M | -39.17M | -42.06M | -56.86M | -60.07M | -63.82M | -76.65M | -70.94M | -54.04M | -57.70M | -58.48M | -52.86M |
| EBITDA | - | - | - | - | - | - | - | - | - | -67.73M | -54.02M | -55.98M | -57.41M | -51.57M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 0 | - | 747.00K | 2.04M | 1.85M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -67.89M | -52.71M | -56.76M | -59.45M | -53.43M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 105.00K | 25.00K | 0 | 0 | 30.00K |
| Net Income | -43.04M | -30.37M | -29.34M | -35.62M | -38.54M | -53.03M | -53.72M | -58.70M | -72.55M | -67.99M | -52.73M | -56.76M | -59.45M | -53.46M |
| Diluted EPS | - | - | -1.06 | -1.22 | -1.28 | -1.14 | -0.34 | -0.37 | -0.45 | -0.42 | -0.33 | -0.35 | -0.35 | -0.30 |
| R&D Expense | - | - | 22.55M | 29.48M | 32.77M | 41.60M | 45.76M | 48.63M | 60.63M | 52.15M | 38.72M | 40.52M | - | 38.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 135.87M | 252.10M | 263.46M | 241.16M |
| Operating Income | -135.87M | -252.10M | -263.46M | -241.16M |
| EBITDA | -135.28M | -251.43M | -262.83M | -233.37M |
| Interest Expense | - | - | - | 3.22M |
| Pretax Income | -130.90M | -235.66M | -243.61M | -236.80M |
| Tax Provision | 0 | 268.00K | 178.00K | 130.00K |
| Net Income | -130.90M | -235.93M | -243.79M | -236.93M |
| Diluted EPS | -0.86 | -3.63 | -1.53 | -1.45 |
| R&D Expense | 91.75M | 142.72M | 200.93M | 176.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 426.23M | 496.19M | 316.97M | 191.05M |
| Current Assets | - | 387.95M | 478.28M | 314.06M | 190.54M |
| Cash & Equivalents | - | 240.94M | 374.04M | 142.15M | 182.53M |
| Inventory | - | - | - | - | - |
| Receivables | 200.00K | 919.00K | 939.00K | - | - |
| Total Liabilities | - | 873.08M | 27.12M | 29.91M | 87.18M |
| Current Liabilities | - | 23.70M | 25.11M | 29.89M | 32.45M |
| Long Term Debt | - | - | - | - | 54.53M |
| Total Debt | - | 8.44M | 5.23M | 1.85M | 55.01M |
| Total Equity | - | -446.85M | 469.08M | 287.06M | 103.87M |
| Shares Outstanding | - | 151.95M | 158.83M | 161.71M | 174.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -114.90M | -163.28M | -182.94M | -206.44M |
| Investing Cash Flow | - | -168.01M | 64.39M | -70.56M | 168.52M |
| Financing Cash Flow | - | 115.74M | 231.94M | 21.60M | 77.09M |
| Capital Expenditure | -817.00K | -511.00K | -117.00K | - | - |
| Free Cash Flow | - | -115.41M | -163.40M | -182.94M | -206.44M |
| Net Change in Cash | - | -167.17M | 133.04M | -231.89M | 39.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 29.3% | -50.3% | -84.9% | -228.1% |
| ROCE % | -33.8% | -53.5% | -91.8% | -152.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NMRA
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQM2NoVXZrcDZVRU96RlBKUmRrbHpXVVA0Vm5OVEx2QlNjcnFpdnlpbzF0OERzSjdIYk90UzBCU3cwRGdBZHpITERYcU8zQkE2YTlPQ3hXSmRuSlNmbkY4cWNfQXdTOVBwRlZvdHJ5Q0ZPUG01SUVvZTAwZlVyei1XTTFxWVM5RGZQeHlWbU…
Why Is BioAge Labs Stock Sinking Friday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPSXZvN0NocEFvRndEekZuYnltVEt4X1B1dWt4N2pUeXpiRnpYZWhiZkNKWWhGQzVNdWVvNGZiVkZKd0JUUlpGR0E4bGgzLXdHaUhhSWY5STMzWXYwanlVLTh2emltT2RPR3BvLWxCWlI5Tno1VlJXTGt4Sk5OdV9DTl9NNzl1bFhERmJRLU…
Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNc2FKUE1Tb2l0R0JrMDFELWMtekFPc2oxZnBTamMxeVlBc1Q0S3Y5T1Fkam1HZ0dWcnNTYlhveHVtNFRmakRjYUVEajFkYjlXWG8zLVZHbVlOeHZvbE9IcXhoQ3ZNRW93R2ZPZWtYUXN1bmw2dDVKVENwSWEwbC1wTVRua09lT0J3QTd1Ml…
Neumora's Repeat NMRA-215 Rat Study Found No Unexpected Adverse Findings - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPVk5SclVULWxZbVpXTlo0c081Wk9kMi15RGxleTl1YXdIVjdxVi03X0Rpb0lLNTB3MlpQNFB5bXZVS0tsUmN4ekhiQVFsQWtsS0hqYTJkRVJ0Nm5JMnNhSTFyZmFSNGdZQ09UNFlvQXV3cVRQcTlqVEVDNU15Q0JsOFVVTXpQUEtLQVY0Uz…
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Stocktwits
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxOSGN5QnJTM05kZDlDbW51SlByZXBjZnd1N1BNaDR5Szdac2Zxc2FLdmdaOTlFSmc3SU9EN0tqNDRZUDlYYWFHaHFnTmRNZnNrdng2Y3lyRjN6RnIzdmladnFkTkVVUnByRmlPdmlUaHo0VjdITFJuMzBOQ1drY2hZQTgxQUNoaFBvWFdJcE…
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud - Business Wire
<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxNMmpnQXY0eWU1ZWdMZEM1Y2hIMm1EdWU5ZGw1dTZ1Z3pBT1RGUnA5YTROU1U3RU9OOVVhYXVlbm0zeU13VnRoNWFjMDJWek5tbVhaS3ZaM2doRzk2Mno2ZHc5dmdJSndlNWR2LVhySU1tNlRtUVA2cDd5MHNkTGhBTUlBeXhkYl9qTXFKN1…
NMRA — Frequently Asked Questions
What is the current share price of NMRA?
As of 2026-08-05 17:25 PDT, NMRA trades at $1.61 on NASDAQ/NYSE. Its 52-week range is $0.92 to $3.59.
What is the market capitalisation of NMRA?
NMRA has a market capitalisation of $280.56M on NASDAQ/NYSE.
What is the P/E ratio of NMRA?
NMRA trades at a trailing price-to-earnings (P/E) ratio of -1.11. Its price-to-book (P/B) ratio is 2.70.
Is NMRA a good stock to buy?
This page provides a data-driven analysis of NMRA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.